Abingworth
Finance · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
38 Jermyn St, London, Greater London, SW...Phone Number
+44 2075341500Website
www.abingworth.comRevenue
$17.4 MillionIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
2
2
2
2
About Abingworth
Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams building world-class companies. The company's therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston.Explore more
Abingworth Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Abingworth your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Abingworth, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Abingworth
Earning: See what the market has to say on Abingworth recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check if Abingworth has recently received funding, and reach out quickly before it becomes old news!
Check out if Abingworth is spiking on competitors!
Product Launch: Get notified when Abingworth launches new products
Funding: Get notified immidiatlly once Abingworth has new funding data
Click to see if Abingworth had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Abingworth
Compare insights from companies similar to Abingworth, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Abingworth is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
Abingworth is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about Abingworth.
Abingworth Tech Stack
A closer look at the technologies used by Abingworth
Most Recent Scoops
Project
Spending/Investment
Lateral Move
Executive Move
Executive Moves, Lateral Move
Lateral Move
Executive Move
Executive Moves, Lateral Move
Project
Spending/Investment
Project
Spending/Investment
Abingworth News & Media
Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development
LONDON, July 08, 2024 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), today announced the closing of its series A financing raising £90m ($114m). The round was co-led by new leading life science investors Novo Holdings and Abingworth. Additional new investors British Patient Capital (a wholly owned commercial subsidiary of British Business Bank plc, the UKAbingworth to Provide Teva with up to $150 Million in Financing to Advance Treatment of Asthma
Abingworth will provide up to $150 million in funding to Teva to offset Teva’s ICS/SABA (TEV-56248) program costs, for the treatment of asthma.Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
LONDON & BOSTON & TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Launch Therapeutics, Inc., today announced a clinical collaboration agreement to further accelerate the clinical research program of Teva’s ICS-SABA (TEV-‘248). Teva and Abingworth, a leading international life sciences investment group, part of global investment firm Carlyle (NASDAQ: CG), today also announced a strategic development funding agreement in which Abingworth provides TAbingworth To Provide Gilead Sciences Up To $210 Million In Funding - Mondaq
The Life Sciences team advised Abingworth (NASDAQ: CG) on its strategic development financing agreement with Gilead Sciences.
Read more news
Top Finance Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Abingworth
Sign Up For FreeTo access detailed company insights
Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams building world-class companies. The company's therapeutic focused investments fall into three categories: seed and early-stage, development stage... Read More
